Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site
The Pharma Data
FEBRUARY 22, 2022
State-of-the-art facility will headquarter research efforts in Boston and New York to accelerate the development of RNA and DNA-based medicines. Adams, vice president of genetic medicine at Lilly and co-director of the Institute. ” The Institute will be headquartered in 334,000 sq.
Let's personalize your content